AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38691387
Drug: Xanomeline-trospium chloride
RxNorm normalized name: trospium
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xanomeline-trospium chloride (maximum dose xanomeline 125 mg/trospium 30 mg)
Trial: 38691622
Drug: Hematopoietic stem
RxNorm normalized name: Umbilical Cord Blood Hematopoietic Stem Cells
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematopoietic stem progenitor cell-gene therapy (HSPC-GT)
Trial: 38691823
Drug: Whole-pelvic radiation
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-pelvic radiation therapy (WPRT)
Trial: 38692113
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction (MBSR) group therapy (n=49)
Trial: 38692292
Drug: Recombinant ADAMTS13
RxNorm normalized name: ADAMTS13, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant ADAMTS13 (40 IU per kilogram of body weight, administered intravenously)
Trial: 38692292
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (plasma-derived products)
Trial: 38692428
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (MBI) tailored for adolescents with T1D; specific dosage and duration not mentioned.
Trial: 38692712
Drug: Clinical pharmacologist-led
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacologist-led intervention including a detailed discharge medication management plan, a circle of care handover and early postdischarge virtual check-up visits to 1 month with 3-month follow-up.
Trial: 38692727
Drug: adalimumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab (160 mg)
Trial: 38693271
Drug: Intraoral cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoral cold water spray
Trial: 38693271
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cold water spray)
Trial: 38693511
Drug: Ambroxol 1800
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 1800 mg/day
Trial: 38693583
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (25 mg/kg), moxifloxacin (400 mg), pyrazinamide, isoniazid, aspirin (150 mg), and steroids for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Trial: 38693583
Drug: Rifampicin, isoniazid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin, isoniazid, pyrazinamide (without aspirin) for 2 months followed by rifampicin, isoniazid, and pyrazinamide for 4 months
Trial: 38693583
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to the National TB Elimination Program guidelines
Trial: 38694503
Drug: XAV-19 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XAV-19 (150 mg)
Trial: 38694999
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine infusions
Trial: 38695107
Drug: Drug-level feedback
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 100 mg in 1 g TOPICAL GEL [Evel Knievels Natural Choice Pain Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-level feedback from urine testing
Trial: 38695107
Drug: White coat
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White coat dosing behavior
Trial: 38695310
Drug: SARS-CoV-2 RBD-based
RxNorm normalized name: RBD SARS-CoV-2 HBsAg VLP vaccine
DrugBank: Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine (DB16431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 RBD-based VLP vaccine (LYB001) at doses of 30 or 60 µg
Trial: 38695310
Drug: SARS-CoV-2 RBD-based
RxNorm normalized name: RBD SARS-CoV-2 HBsAg VLP vaccine
DrugBank: Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine (DB16431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 RBD-based protein subunit vaccine (ZF2001, control group)
Trial: 38695479
Drug: Lenvatinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib + pembrolizumab + chemotherapy
Trial: 38695527
Drug: Mavacamten dose-titration
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mavacamten dose-titration regimen guided by echocardiographic measures
Trial: 38695604
Drug: SQZ-PBMC-HPV (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQZ-PBMC-HPV (administered as monotherapy every 3 weeks)
Trial: 38696122
Drug: Osilodrostat (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osilodrostat (starting dose: 2 mg bid; maximum: 30 mg bid)
Trial: 38696203
Drug: Combined Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined Nicotine Replacement Therapy (CNRT)
Trial: 38696203
Drug: Combined Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined Nicotine Replacement Therapy (CNRT) and Varenicline
Trial: 38696221
Drug: Intranasal (R,S)-Ketamine
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (R,S)-Ketamine
Trial: 38696657
Drug: Inspiratory training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory training, details on dosage and duration not available
Trial: 38696672
Drug: Ultra-Rapid Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultra-Rapid Lispro Insulin with Control-IQ Technology
Trial: 38697155
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (5·4 mg/kg intravenously once every 21 days)
Trial: 38697155
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician's choice (capecitabine, lapatinib, or trastuzumab)
Trial: 38697156
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg) plus gemcitabine and cisplatin
Trial: 38697182
Drug: AHCL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHCL therapy (MiniMed 780G)
Trial: 38697184
Drug: Setmelanotide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setmelanotide (3.0 mg, subcutaneously once a day for 16 weeks)
Trial: 38697216
Drug: Uniform Multidrug
RxNorm normalized name: Eugenia uniflora whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniform Multidrug Therapy (U-MDT) for 6 months
Trial: 38697216
Drug: Regular Multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Multidrug Therapy (R-MDT) for 12 months
Trial: 38697618
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg by mouth twice daily and capecitabine 1000 mg/m2 by mouth twice daily
Trial: 38697677
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of once-weekly online Singing for Lung Health (SLH) sessions
Trial: 38697766
Drug: Hospital at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital at home treatment
Trial: 38698396
Drug: 6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml iPAAG injection
Trial: 38698433
Drug: Active spinal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active spinal manual therapy
Trial: 38698433
Drug: Placebo-control spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-control spinal manual therapy
Trial: 38698442
Drug: Supplemental enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition to achieve a high amount of enteral protein (2-2.4 g/kg/day)
Trial: 38698442
Drug: No supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplemental enteral protein to achieve a moderate amount of enteral protein (0.8-1.2 g/kg/day)
Trial: 38698442
Drug: Supplemental enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental enteral protein (1.2 g/kg/day)
Trial: 38698639
Drug: DopaFuse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DopaFuse therapy (continuous delivery of levodopa/carbidopa)
Trial: 38698639
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral levodopa/carbidopa administration
Trial: 38762720
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI)
Trial: 38699346
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment without phone-based MI
Trial: 38762720
Drug: Duloxetine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine monotherapy
Trial: 38699828
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and metronidazole
Trial: 38699939
Drug: Cedirogant 75
RxNorm normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cedirogant 75 mg
Trial: 38699939
Drug: Cedirogant 150
RxNorm normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cedirogant 150 mg
Trial: 38699939
Drug: Cedirogant 375
RxNorm normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cedirogant 375 mg
Trial: 38700579
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of rh-endostatin (210 mg) over a period of 120 hours combined with platinum-based doublet chemotherapy (pemetrexed or paclitaxel) in 21-day cycles.
Trial: 38700630
Drug: 10-day bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day bismuth-containing quadruple therapy
Trial: 38701812
Drug: Hydroxyurea (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (17.5 ± 2.5 mg/kg per day for 6 months, followed by dose escalation up to 20-35 mg/kg per day)
Trial: 38701812
Drug: Hydroxyurea dose
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea dose escalation to MTD with dose optimisation
Trial: 38701881
Drug: Withdrawing neurohormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawing neurohormonal blockers
Trial: 38701881
Drug: Neurohormonal blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurohormonal blockers (control group)
Trial: 38701961
Drug: Down Sizing
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Down Sizing Strategy (HANGZHOU Solution)
Trial: 38702761
Drug: SABR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABR with MRI guided focal dose intensification
Trial: 38702828
Drug: Neoadjuvant niraparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant niraparib treatment
Trial: 38702828
Drug: Neoadjuvant platinum-taxane
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant platinum-taxane doublet chemotherapy
Trial: 38702961
Drug: Sodium channel
RxNorm normalized name: Sodium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium channel blockers (SCBs) - flecainide or propafenone
Trial: 38703010
Drug: Nirogacestat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirogacestat (150 mg, twice-daily, continuous 28-day cycles)
Trial: 38703010
Drug: Nirogacestat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirogacestat (150 mg)
Trial: 38703782
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with SARS-CoV-2 in a stepwise dose escalation controlled human infection model (CHIM) with a dose of 1×10
Trial: 38703993
Drug: FDA-approved anti-angiogenic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA-approved anti-angiogenic agents combined with immunotherapy and nanocarrier-mediated targeted therapy
Trial: 38705163
Drug: Artemether-lumefantrine with
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine with primaquine (0.25 mg/kg)
Trial: 38705163
Drug: Sulfadoxine-pyrimethamine plus
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine (1.66 mg/kg)
Trial: 38705167
Drug: Seralutinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seralutinib (60 mg twice daily for 2 weeks, then increased to 90 mg twice daily as tolerated)
Trial: 38705167
Drug: Placebo (dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dry powder inhaler, twice daily for 24 weeks)
Trial: 38705804
Drug: Ad26.COV2.S (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S (various dose levels)
Trial: 38705804
Drug: Ad26.COV2.S (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S (single dose schedule)
Trial: 38706247
Drug: Cadonilimab 10
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 10 mg/kg every three weeks (Q3 W) for up to 24 months until progressive disease (PD) or adverse events (AE) discovery.
Trial: 38706390
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (one intravenous injection)
Trial: 38706390
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one injection of saline solution)
Trial: 38706610
Drug: LMB-100 (30-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMB-100 (30-minute infusion on days 4, 6, and 8 at doses of 100 and 140 µg/kg) + tofacitinib (10 mg BID for the first 10 days of the cycle)
Trial: 38706611
Drug: QUS-radiomics model-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUS-radiomics model-guided adaptive chemotherapy (experimental arm)
Trial: 38706726
Drug: Dose intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose intensified sRT (64 Gy vs 70 Gy)
Trial: 38707876
Drug: Lateral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral Suspension (LS)
Trial: 38708017
Drug: Group hypnosis
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group hypnosis program for stress reduction (5 weekly sessions) plus 5 hypnosis audio recordings and an educational booklet on coping with stress
Trial: 38708072
Drug: PWP co-facilitated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWP co-facilitated intervention delivered over six weekly sessions
Trial: 38708959
Drug: Non-pooled, multidonor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pooled, multidonor faecal microbiota transplantation (FMT) for 4 weeks, delivered daily by enema for 2 weeks, followed by every second day for 2 weeks.
Trial: 38709006
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir with oral lead-in (OLI)
Trial: 38709006
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir without oral lead-in (OLI)
Trial: 38709212
Drug: Sequential dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential dosing of sacituzumab govitecan (SG) followed by talazoparib (TZP)
Trial: 38709212
Drug: Concurrent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent dosing of sacituzumab govitecan (SG) with talazoparib (TZP)
Trial: 38709220
Drug: FAP-IL2v 10
RxNorm normalized name: AVA-6000 (FAP-activated doxorubicin prodrug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAP-IL2v 10 mg plus atezolizumab 1,200 mg intravenously every 3 weeks
Trial: 38709220
Drug: FAP-IL2v weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FAP-IL2v weekly for 4 weeks and then every 2 weeks plus atezolizumab 840 mg intravenously every 2 weeks
Trial: 38709228
Drug: EDIT-101 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDIT-101 (low dose)
Trial: 38709228
Drug: EDIT-101 (intermediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDIT-101 (intermediate dose)
Trial: 38709228
Drug: EDIT-101 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDIT-101 (high dose)
Trial: 38709456
Drug: Intraoperative haemoadsorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery
Trial: 38709500
Drug: Cytisinicline, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline, 3 mg, taken 3 times daily (n=107)
Trial: 38709986
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg once daily for 6 weeks, titrated to 10 mg once daily for 18 weeks)
Trial: 38709999
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) selected by noncontrast CT (NCCT)
Trial: 38710185
Drug: Garadacimab 200
RxNorm normalized name: Garadacimab
DrugBank: Garadacimab (DB15629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garadacimab 200 mg once monthly
Trial: 38710185
Drug: Garadacimab 600
RxNorm normalized name: Garadacimab
DrugBank: Garadacimab (DB15629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garadacimab 600 mg once monthly
Trial: 38710187
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg every 3 weeks by intravenous infusion)
Trial: 38710192
Drug: Herpes zoster
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herpes zoster subunit vaccine (0.5 mL intramuscular injection) at weeks 0 and 8
Trial: 38710192
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mL intramuscular injection) at weeks 0 and 8
Trial: 38710192
Drug: Herpes zoster
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herpes zoster subunit vaccine
Trial: 38710269
Drug: 1-g conjugated
RxNorm normalized name: estrogens, conjugated (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g conjugated estrogen cream (0.625 mg/g), inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Trial: 38710269
Drug: Placebo cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively
Trial: 38710269
Drug: 1-g conjugated
RxNorm normalized name: estrogens, conjugated (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g conjugated estrogen cream (0.625 mg/g)
Trial: 38710325
Drug: Preoperative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative ketamine 0.5 mg/kg intravenous bolus
Trial: 38710445
Drug: HSP+ (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSP+ (45 g HSP + 5 g HSP-derived bioactive peptides/d)
Trial: 38710445
Drug: HSP (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSP (50 g HSP/d)
Trial: 38710445
Drug: Casein (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (50 g casein/d)
Trial: 38710487
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg once daily (QD) 3 days on, 4 days off (160 3/4)
Trial: 38710487
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg QD 3 days on, 4 days off (120 3/4)
Trial: 38710487
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg QD 3 days on, 4 days off, 2 weeks on, 1 week off (160 3/4, 2/1w)
Trial: 38710537
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate sodium (137 mEq/L)
Trial: 38710537
Drug: Standard dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysate sodium (140 mEq/L)
Trial: 38710539
Drug: Traditional systemic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional systemic treatment
Trial: 38710539
Drug: Nonsystemic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsystemic treatment
Trial: 38710583
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive non-surgical therapy (MINST)